eligibility_summary
Key eligibility: Adults with relapsed/refractory multiple myeloma (IMWG) and ECOG 0–1, contraception/abstinence required. Key exclusions: prior cevostamab/FcRH5 agent or elranatamab, prior allogeneic SCT, high circulating plasma cells (>500/mL or >5% WBC), WM/POEMS, amyloidosis, autoimmune disease, PML, significant neuropathy, chronic CMV/EBV, HLH/MAS, HBV/HCV, HIV, CNS myeloma, significant cardiovascular disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase Ib, open-label trial in relapsed/refractory multiple myeloma testing: 1) Cevostamab (IV) + elranatamab (SC), with step-up dosing, and 2) an elranatamab monotherapy cohort. Cevostamab: IgG-like bispecific T-cell–redirecting antibody that binds FcRH5 on myeloma/plasma cells and CD3 on T cells, inducing T cell–mediated cytotoxicity. Elranatamab: IgG-like bispecific T-cell engager targeting BCMA on myeloma cells and CD3, triggering T-cell activation and lysis of tumor cells. Tocilizumab (anti–IL-6 receptor monoclonal antibody) is used as rescue for cytokine release syndrome. Targeted cells/pathways: malignant plasma cells expressing FcRH5 and/or BCMA, T-cell activation via CD3 signaling, IL-6 pathway blockade for CRS management. Primary aim: safety/PK and RP2R.